证券代码：300677 证券简称：英科医疗 公告编号：2025-059 英科医疗科技股份有限公司 关于变更注册资本暨修订《公司章程》的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三次会议、第四届监事会第三次会议，审议 通过了《关于变更注册资本暨修订<公司章程>的议案》，拟对《英科 医疗科技股份有限公司章程》（以下简称"《公司章程》"）的相关 条款进行修订。具体情况如下： 一、公司注册资本变更情况 综上，公司注册资本将在本次变更回购股份用途及注销完成后， 由人民币 64,617.4737 万元变更为人民币 64,170.0369 万元，同时需对 照修订《公司章程》有关条款。 二、《公司章程》修订情况 本次《公司章程》相关条款作如下修订： | 原章程内容 | | 修订后章程内容 | | --- | --- | --- | | 第六条 | 公司注册资本为人 | 第六条 公司注册资本为人 | | 民币 64,617.4737 | 万元。 | 民币 64,170.0369 ...

山东英科医疗制品有限公司（以下简称"山东英科"）因经营需 要，向招商银行股份有限公司潍坊分行（以下简称"招商银行潍坊分 行"）申请授信额度，公司为上述授信提供人民币 10,000 万元的连带 责任保证担保，并于近日与招商银行潍坊分行签订了《最高额不可撤 销担保书》（以下简称"保证合同二"）。 注：（1）以上表格中最近一期数据均采用2025年3月31日数据（未经审计）； 证券代码：300677 证券简称：英科医疗 公告编号：2025-061 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开的第三届董事会第二十一次（定 期）会议、第三届监事会第十九次（定期）会议以及 2023 年度股东 大会，审议通过了《关于公司及子公司向银行申请授信额度及担保事 项的议案》。为满足公司及子公司的生产经营需要，公司及子公司拟 向银行等金融机构申请综合授信的额度以及金融衍生品交易风险限 额的总额（以下简称"授信额 ...

2025 年第一季度报告披露提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三次会议和第四届监事会第三次会议，审 议通过了《关于<2025 年第一季度报告>的议案》。 证券代码：300677 证券简称：英科医疗 公告编号：2025-056 英科医疗科技股份有限公司 为使投资者全面了解报告期内公司的经营情况和财务状况，公司 《2025 年第一季度报告》将于 2025 年 4 月 29 日在巨潮资讯网 （www.cninfo.com.cn）披露，敬请投资者注意查阅。 特此公告。 英科医疗科技股份有限公司 董 事 会 2025 年 4 月 29 日 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-060 英科医疗科技股份有限公司 关于召开公司 2025 年第三次临时股东大会的通知 3、会议召开的合法、合规性：本次股东大会的召开符合有关法 律、法规、部门规章、规范性文件及《英科医疗科技股份有限公司章 程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）14:00 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交 易所交易系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-9:25， 9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网系统投票的具 体时间为 2025 年 5 月 16 日 9:15-15:00。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三次会议，审议通过了《关于召开公司 2025 年第三次临时股东大会的议案》，公司决定于 2025 年 5 月 16 日 （星期五）14 ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-055 英科医疗科技股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第四届监事会 第三次会议于 2025 年 4 月 28 日在公司会议室以通讯方式召开，会议 通知已于 2025 年 4 月 26 日以专人送达、电子邮件、传真或即时通讯 工具等形式向全体监事发出。会议由公司监事会主席唐烨先生召集和 主持，本次会议应出席监事 3 名，实际出席会议监事 3 名。会议的召 集和召开符合《中华人民共和国公司法》《英科医疗科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 1、审议通过《关于<2025年第一季度报告>的议案》 监事会认为：公司《2025年第一季度报告》的编制程序符合法律、 行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 报告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗 漏。 1 具体内容详见同日刊登于巨潮资讯网（www.c ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-058 英科医疗科技股份有限公司 关于变更回购股份用途并注销的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三次会议、第四届监事会第三次会议，审议 通过了《关于变更回购股份用途并注销的议案》，拟对于 2023 年 7 月 13 日召开的第三届董事会第十五次会议、第三届监事会第十四次 会议审议通过的《关于公司回购股份方案的议案》的回购股份（以下 简称"2023 年回购"）用途进行变更，由"用于实施员工持股计划及 /或股权激励"变更为"减少公司注册资本"，并将对 2023 年回购的 全部股份，共计 4,504,300 股予以注销。本事项尚需提交公司股东大 会审议，现将有关事项说明如下： 一、回购股份概述 1、公司于 2023 年 7 月 13 日召开第三届董事会第十五次会议和 第三届监事会第十四次会议，审议通过了《关于公司回购股份方案的 议案》，同意公司使用不低于人民币 10,000 万元（含本数）且不超 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥2,493,933,645.56, representing a 13.20% increase compared to ¥2,203,087,168.00 in the same period last year[4] - Net profit attributable to shareholders was ¥352,721,895.21, up 48.08% from ¥238,197,783.00 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 53.22%, amounting to ¥246,606,613.51 compared to ¥160,950,736.00 in the previous year[4] - Basic earnings per share rose to ¥0.55, a 52.78% increase from ¥0.36 in the previous year[4] - Net profit for the current period was ¥361,372,917.73, representing a significant increase of 50.2% from ¥240,565,774.00 in the previous period[21] - Basic and diluted earnings per share increased to 0.55 from 0.36, representing a growth of 52.78% year-over-year[22] Cash Flow - The net cash flow from operating activities surged by 150.73%, totaling ¥406,102,817.23, compared to ¥161,970,968.00 in the same period last year[4] - Operating cash inflow totaled approximately ¥2.72 billion, up from ¥2.40 billion, reflecting an increase of 13.43%[23] - Total cash outflow for operating activities was approximately ¥2.31 billion, compared to ¥2.24 billion in the previous period, an increase of 3.23%[23] - Cash flow from investing activities showed a net outflow of ¥2.26 billion, a decline from a net inflow of ¥682.93 million in the prior period[24] - Cash flow from financing activities generated a net inflow of approximately ¥2.63 billion, compared to ¥2.23 billion in the previous year, indicating an increase of 18.14%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥37,286,999,455.90, reflecting a 7.67% increase from ¥34,630,896,412.44 at the end of the previous year[4] - Current liabilities rose to ¥16,932,585,772.68, up from ¥14,682,518,276.02, indicating an increase of 15.3%[18] - Non-current liabilities totaled ¥2,312,364,439.73, slightly up from ¥2,266,697,098.47, reflecting a growth of 2.0%[18] - The company's total equity increased to ¥18,042,049,243.49, compared to ¥17,681,681,037.95, showing a growth of 2.0%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,786[10] - The largest shareholder, Liu Fangyi, holds 35.86% of the shares, amounting to 231,703,107 shares, with 7,650,000 shares pledged[10] - The company reported a total of 177,081,960 shares subject to lock-up at the end of the period, down from 177,152,329 shares, a reduction of about 0.04%[13] - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[12] - The company has not identified any related party relationships among the top shareholders[13] Other Financial Metrics - The company reported non-recurring gains of ¥106,115,281.70, primarily from government subsidies and fair value changes of financial assets[6] - Research and development expenses for the current period were ¥99,551,616.56, compared to ¥84,578,719.00, an increase of 17.7%[21] - The company reported a financial income of ¥131,053,333.02, up from ¥99,403,769.00, reflecting a growth of 32.0%[21] - Other comprehensive income after tax was -¥5,676,841.42, compared to ¥3,370,903.00 in the previous period, indicating a decline[21] Cash and Investments - The company's cash and cash equivalents decreased to ¥11,818,079,821.89 from ¥12,014,011,946.78, reflecting a decline of approximately 1.63%[16] - Trading financial assets increased significantly to ¥9,167,759,033.53 from ¥6,737,459,715.11, marking a growth of about 36.93%[16] - Accounts receivable rose to ¥1,437,681,488.31 from ¥1,362,747,313.74, indicating an increase of approximately 5.49%[16] - The company’s prepayment items increased to ¥222,986,278.24 from ¥204,297,475.65, reflecting a growth of approximately 9.00%[16] - The company’s other receivables increased to ¥93,649,636.68 from ¥78,326,027.38, showing an increase of about 19.53%[16]

作为全球一次性手套行业的领军企业，英科医疗始终将可持续发展视为企业基因。近日，英科医疗（股 票代码：300677）连续第四年发布《2024年度环境、社会和公司治理（ESG）报告》（以下简称"报 告"），系统性地呈现了其在技术突破、绿色实践、员工关怀及合规治理等维度的深度探索。 ESG 即环境（Environment）、社会（Social）和公司治理（Governance），ESG报告也被称为上市公司 的"第二财报"，是衡量企业社会责任及驱动长期价值增长的关键要素。 报告显示，英科医疗在ESG实践中成果卓著，荣获"A 股医疗器械上市公司ESG TOP20""2024年度上市 公司ESG价值传递奖""金羚奖2024年度ESG创新领军企业"等荣誉；在ESG评级与认证方面，WIND授予 其A级评级，MSCI ESG评定其为BBB级。另外，公司还成功斩获2024年度EcoVadis"COMMITTED"徽 章，进一步提升了行业影响力与公信力。 | MICO | | | | | | --- | --- | --- | --- | --- | | 2024, 可持续发展足迹 | | | | | | 环境E | | | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve significant growth in 2024, with revenue projected at 9.523 billion yuan (up 37.65% year-on-year) and net profit attributable to shareholders at 1.465 billion yuan (up 282.63 year-on-year) [6] - The growth is driven by industry inventory digestion, the elimination of outdated production capacity, and a 100% capacity utilization rate, alongside a recovery in glove prices [6] - The company has a strong cost and capacity advantage, with a global expansion strategy that mitigates geopolitical risks [6] - The disposable glove market is expected to grow, with global sales projected to reach 82.93 billion units and revenue of 13.6 billion USD in 2025 [7] Financial Summary - Revenue for 2024 is expected to be 9.523 billion yuan, with a year-on-year growth of 37.6% [9] - Net profit for 2024 is projected at 1.465 billion yuan, reflecting a year-on-year increase of 282.6% [9] - The gross margin for personal protective equipment is 24.24%, an increase of 10.96 percentage points [6] - The company’s earnings per share (EPS) for 2025 is estimated at 2.49 yuan, with a price-to-earnings (P/E) ratio of 9.0 [6][9] Production Capacity and Technology - The company's total production capacity for disposable gloves is expected to reach 87 billion units in 2024, a year-on-year increase of 5.33% [8] - The company operates six production bases in China, with advanced production technology and automation ensuring high efficiency and low energy consumption [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6][18] Core Views - The company is expected to achieve significant revenue growth in 2024, with projected revenue of 95.23 billion yuan, representing a year-over-year increase of 37.65%. The net profit attributable to shareholders is forecasted to reach 14.65 billion yuan, a substantial increase of 282.63% year-over-year [6][9] - The company has a strong cost and capacity advantage, with a capacity utilization rate reaching 100%. The recovery in glove prices and the elimination of outdated production capacity in the industry are key factors driving growth [6][7] - The company is expanding its production capacity and has a global layout that mitigates geopolitical risks. The demand for nitrile gloves is expected to rise, with global sales projected to reach 829.3 billion pieces in 2025 [7][8] Financial Summary - Revenue for 2024 is projected at 95.23 billion yuan, with a year-over-year growth of 37.65%. The net profit attributable to shareholders is expected to be 14.65 billion yuan, reflecting a year-over-year increase of 282.63% [6][9] - The gross margin for personal protective equipment is 24.24%, an increase of 10.96 percentage points, while the gross margin for rehabilitation care products is 15.37%, up by 2.54 percentage points [6] - The company’s earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 2.49 yuan, 2.94 yuan, and 3.46 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 9.0, 7.6, and 6.5 [6][9] Industry Outlook - The global market for disposable gloves is expected to grow significantly, with nitrile gloves leading in both volume and price recovery post-pandemic. The Chinese nitrile glove market has clear growth logic, with expectations for both volume and price increases [7][8] - The company is strategically positioned in the upstream raw material supply chain, ensuring stable supply for glove production [7]